{"title":"新的肿瘤细胞毒药物和靶点。","authors":"J H Beijnen","doi":"10.1007/BF01962548","DOIUrl":null,"url":null,"abstract":"<p><p>New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth.</p>","PeriodicalId":19804,"journal":{"name":"Pharmaceutisch weekblad. Scientific edition","volume":"14 4A","pages":"258-67"},"PeriodicalIF":0.0000,"publicationDate":"1992-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF01962548","citationCount":"1","resultStr":"{\"title\":\"New cytotoxic drugs and targets in oncology.\",\"authors\":\"J H Beijnen\",\"doi\":\"10.1007/BF01962548\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth.</p>\",\"PeriodicalId\":19804,\"journal\":{\"name\":\"Pharmaceutisch weekblad. Scientific edition\",\"volume\":\"14 4A\",\"pages\":\"258-67\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/BF01962548\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutisch weekblad. Scientific edition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF01962548\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutisch weekblad. Scientific edition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF01962548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
